Joël Jean-Mairet
Oprichter bij Ysios Capital Partners SGEIC SA
Oorsprong van het eerstegraads netwerk van Joël Jean-Mairet
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.
24
| Private Company | Investment Managers | 24 |
16
| Holding Company | Medical Specialties | 16 |
Public Company | Biotechnology | 15 | |
Public Company | Biotechnology | 14 | |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA.
11
| Subsidiary | Biotechnology | 11 |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.
10
| Subsidiary | Biotechnology | 10 |
Medlumics SL
Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.
9
| Holding Company | Medical Specialties | 9 |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.
9
| Holding Company | Pharmaceuticals: Major | 9 |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.
9
| Holding Company | Biotechnology | 9 |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.
9
| Holding Company | Biotechnology | 9 |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain.
8
| Holding Company | Medical Specialties | 8 |
Methinks Software SL
Methinks Software SL Packaged SoftwareTechnology Services Methinks Software SL provides universal and timely diagnosis to enable life-saving treatments worldwide. The company is based in Barcelona, Spain. The Spanish company's first focus is on stroke, the second cause of death and a major cause of disability in the world. The company was founded by Cristian Martí. Pau Rodríguez has been the CEO of the company since 2019.
4
| Holding Company | Packaged Software | 4 |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.
2
| Subsidiary | Pharmaceuticals: Generic | 2 |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Joël Jean-Mairet via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
Université Catholique de Louvain | College/University | Chairman Graduate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Chief Executive Officer Director/Board Member | |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
University of Barcelona | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Graduate Degree | |
Instituto de Estudios Superiores de la Empresa | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Oxford | College/University | Graduate Degree Doctorate Degree | |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ZENTALIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chairman | |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
SwedenBIO Service AB
SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
OREXO AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
Novavax AB
Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Pharmaceuticals: Generic | Chief Executive Officer Chief Executive Officer | |
IMMUNOCORE HOLDINGS PLC | Biotechnology | Founder Chief Operating Officer | |
SYNACT PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
SENSORION | Pharmaceuticals: Major | Chairman Director/Board Member | |
Caixa Capital Risc SGEIC SA
Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital subsidiary of Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Investment Managers | Private Equity Investor Private Equity Investor | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Comptroller/Controller/Auditor | |
Kurma Partners SA
Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Universidad Complutense de Madrid | College/University | Graduate Degree Doctorate Degree | |
FlowCardia, Inc.
FlowCardia, Inc. Medical SpecialtiesHealth Technology FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Founder | |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
MERUS N.V. | Biotechnology | Chairman Chief Operating Officer | |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
Arthur D. Little, Inc.
Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Universidad Autónoma de Madrid | College/University | Doctorate Degree Undergraduate Degree | |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Masters Business Admin Undergraduate Degree | |
University of Deusto | College/University | Masters Business Admin Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 12 |
Spanje | 11 |
Frankrijk | 8 |
Nederland | 6 |
België | 6 |
Sectoraal
Health Technology | 32 |
Consumer Services | 10 |
Commercial Services | 7 |
Finance | 5 |
Operationeel
Director/Board Member | 554 |
Corporate Officer/Principal | 161 |
Chairman | 116 |
Independent Dir/Board Member | 103 |
Chief Executive Officer | 69 |
Sterkste connecties
Insiders | |
---|---|
James Noble | 39 |
Kapil Dhingra | 39 |
Cristina Garmendia Mendizábal | 38 |
Baron Jean Stéphenne | 36 |
Karen Wilson | 31 |
Russell Greig | 31 |
David Kabakoff | 30 |
Rémi Droller | 29 |
Mounia Chaoui-Roulleau | 27 |
Fouad Azzam | 25 |
Wolfgang Reim | 24 |
Sven Arne Andréasson | 24 |
Guido Magni | 23 |
Joseph Turner | 22 |
Ashok Dhanrajgir | 21 |
- Beurs
- Insiders
- Joël Jean-Mairet
- Bedrijfsconnecties